B7-2 expression on tumor cells is important for the acquisition of cytotoxic T lymphocyte activity by spleen cells from low-dose-melphalan- treated MOPC-315 tumor bearers via a mechanism that requires either B7-1 or B7-2 expression on host antigen-presenting cells

Cancer Immunology Immunotherapy

Volumn 49, Issue 1, 2000, Pages 10-22

  Sojka, Dorothy K ^a   La Motte, Ross N ^a   Mokyr, Margalit B ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Chemotherapy induced immunopotentiation; Costimulatory molecules; CTL activity

Indexed keywords

B7 ANTIGEN; CD86 ANTIGEN; MELPHALAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ARTICLE; CANCER IMMUNOLOGY; CELL ACTIVITY; CELL STIMULATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; IMMUNOPOTENTIATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; T LYMPHOCYTE ACTIVATION; TUMOR CELL;

EID: 0033917007     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620050022     Document Type: Article

References (41)

1. Allison JP, Hurwitz AA, Leach DR (1995) Manipulation of costimulatory signals to enhance antitumor T-cell responses. Curr Opin Immunol 7: 682
2. Azuma M, Cayabyab M, Buck D, Phillips JH, Lanier LL (1992) Involvement of CD28 in MHC-unrectricted cytotoxicity mediated by a human natural killer leukemic cell line. J Immunol 149: 1115
3. Bartik MM, Ahn M-C, Baumgartel BA, Hendricks RL, Mokyr MB (1990) Presence of an enlarged pool of MOPC-315-specific cytotoxic T lymphocyte precursors in the thymuses of mice that eradicated a large MOPC-315 tumor as a consequence of low-dose melphalan therapy. Cancer Immunol Immunother 32: 143
4. Ben-Efraim S, Bocian RC, Mokyr MB, Dray S (1983) Increase in the effectiveness of melphalan therapy with progression of MOPC-315 plasmacytoma tumor growth. Cancer Immunol Immunother 15: 101
5. Berd D, Mastrangelo MJ (1988) Active immunotherapy of human melanoma exploiting the immunopotentiating effects of cyclophosphamide. Cancer Invest 6: 337
6. Bluestone JA (1995) New perspectives of CD28-b7-mediated T cell costimulation. Immunity 2: 555
7. Chambers BJ, Wilson JL, Salcedo M, Markovic K, Bejarano MT, Ljunggren HG (1998) Triggering of natural killer cell mediated cytotoxicity by costimulatory molecules. Curr Top Microbiol Immunol 230: 53
8. Chen L, Linsley PS, Hellström KE (1993) Costimulation of T cells for tumor immunity. Immunol Today 14: 483
9. Chen L, McGowan P, Ashe S, Johnston J, Li Y, Hellström I, Hellström KE (1994) Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J Exp Med 179: 523
10. + TCR-transgenic T cells. J Immunol 161: 5268
11. Freeman GJ, Borriello F, Hodes RJ, Reiser H, Hathcock KS, Laszlo G, McKnight AJ, Kim J, Du L, Lombard DB, Gray GS, Nadler LM, Sharpe AH (1993) Uncovering of functional alternative CTLA-4 counter-receptor in B7-deficient mice. Science 262: 907
12. Gajewski TF, Fallarino F, Uyttenhove C, Boon T (1996) Tumor rejection requires a CTLA4 ligand provided by the host or expressed on the tumor: Superiority of B7-1 over B7-2 for active tumor immunization. J Immunol 156: 2909
13. Geldhofn AB, Raes G, Bakkus M, Devos S, Thielemans K, De Baetselier P (1995) Expression of B7-1 by highly metastatic mouse T lymphomas induces optimal natural killer cell-mediated cytotoxicity. Cancer Res 55: 2730
14. Gorelik L, Mokyr MB (1995) Low-dose melphalan-induced up-regulation of type-1 cytokine expression in the s.c. tumor nodule of MOPC-315 tumor bearers and the role of interferon-γ in the therapeutic outcome. Cancer Immunol Immunother 41: 363
15. Greenfield SC, Howard E, Freeman GJ, Kuchroo VK (1999) B7-2 expressed on EL4 lymphoma suppresses antitumor immunity by an interleukin 4-dependent mechanism. J Exp Med 189: 919
16. Hengst JCD, Mokyr MB, Dray S (1981) Cooperation between cyclophosphamide tumoricidal activity and host antitumor immunity in the cure of mice bearing large MOPC-315 tumors. Cancer Res 41: 2163
17. Hodge JW, Abrams S, Schlom J, Kantor A (1994) Induction of antitumor immunity by recombinant vaccinia viruses expressing B7-1 or B7-2 costimulatory molecules. Cancer Res 54: 5552
18. + T cell effectors: Amplification of the lytic potential by B7. J Immunol 163: 2999
19. Ksander BR, Streilein JW (1990) Failure of infiltrating precursor cytotoxic T cells to acquire direct cytotoxic function in immunologically privileged sites. J Immunol 145: 2057
20. La Motte RN, Sharpe AH, Bluestone JA, Mokyr MB (1998) Importance of B7-1-expressing host antigen-presenting cells for the eradication of B7-2 transfected P815 tumor cells. J ImmuNol 161: 6552
21. + T cell-dependent mechanism. J Immunol 162: 4817
22. Marzo AL, Lake RA, Lo D, Sherman L, McWilliam A, Nelson D, Robinson BWS, Scott B (1999) Tumor antigens are constitutively presented in the draining lymph nodes. J Immunol 162: 5838
23. Miller SD, Vanderlung CL, Lenschow DJ, Pope JG, Karandikar NJ, Dal Canto MC, Bluestone JA (1995) Blockade of CD28/B7-1 interaction prevents epitope spreading and clinical relapses of murine EAE. Immunity 3: 739
24. Mokyr MB, Barker E (1986) Specificity of the generation and expresssion of enhanced anti-plasmacytoma immunity by spleen cells from melphalan-treated MOPC-315 tumor bearers. Cancer Immunol Immunother 23: 11
25. + T-cells in the curative effectiveness of a low dose of melphalan for mice bearing a large MOPC-315 tumor. Cancer Res 49: 4597
26. Mokyr MB, Kalinichenko TV, Gorelik L, Bluestone JA (1998) Importance of B7-2 molecule for low dose melphalan-induced acquisition of tumor-eradicating immunity by mice bearing a large MOPC-315 tumor. J Immunol 160: 1866
27. + cells in the cure of mice bearing a large MOPC-315 tumor by low-dose melphalan. J Immunol 151: 4838
28. Matulonis U, Dosiou CC, Freeman G, Lamont C, Mauch P, Nadler LM, Griffin JD (1996) B7-1 is superior to B7-2 costimulation in the induction and maintenance of t-cell-mediated antileukemic immunity. J Immunol 156: 1126
29. Morikawa K, Hosokawa M, Hamada J, Sugawara M, Kobayashi H (1985) Host-mediated therapeutic effects produced by appropriately timed administration of bleomycin on a rat fibrosarcoma. Cancer Res 45: 1502
30. Nishio M, Spielman J, Lee RK, Nelson DL, R. Podack ER (1996) CD80 (B7.1) and CD54 (intracellular adhesion molecule-1) induce target cell susceptibility to promiscuous cytotoxic T cell lysis. J Immunol 157: 4347
31. + T-cells to cause regression of an advanced lymphoma. Immunology 71: 90
32. Razi-Wolf Z, Freeman GJ, Galvin F, Benacerraf B, Nadler L, Reiser H (1992) Expression and function of the murine B7 antigen, the major costimulatory molecule expressed by peritoneal exudate cells. Proc Natl Acad Sci USA 89: 4210
33. Sahasrabudhe DM, deKernion JB, Pontes JE, Ryan DM, O'Donnell RW, Marquis DM, Mudholkar GS, McCune CS (1986) Specific immunotherapy with suppressor function inhibition for metastatic renal cell carcinoma. J Biol Response Modif 5: 581
34. Sharpe AH (1995) Analysis of lymphocyte costimulation in vivo using transgenic and 'knockout' mice. Curr Opin Immunol 7: 389
35. + T-cells in eradication of a large subcutaneous MOPC-315 tumor following low-dose melphalan therapy. Cancer Res 50: 7641
36. Thompson CB (1995) Distinct roles for the costimulatory ligands B7-1 and B7-2 in T helper cell differentiation? Cell 81: 979
37. + T cells by B7-transfected melanoma cells. Science 259: 368
38. + splenic T cells from melphalan-treated BALB/c mice bearing a large MOPC-315 tumor. Cancer Immunol Immunother 31: 129
39. Yang G, Hellstrom KK, Hellstrom I, Chen L (1995) Antitumor immunity elicited by tumor cells transfected with B7-2, a second ligand for CD28/CTLA-4. J Immunol 154: 2794
40. Yang G, Mizuno MT, Hellstrom KE, Chen L (1997) B7-negative versus B7-positive P815 tumor. Differential requirements for priming of an antitumor immune response in lymph nodes. J Immunol 158: 851
41. Yuan L, Kuramitsu Y, Li Y, Kobayashi M, Hosokawa M (1995) Restoration of interleukin-2 production in tumor-bearing rats through reduction of tumor-derived transforming growth factor β by treatment with bleomycin. Cancer Immunol Immunother 41: 355